Gheath AL-Atrash, MD, PhD

Scientific/Medical Founder of TZ102 T-Cell Therapy

Dr. Al-Atrash is a physician-scientist at The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy. He is clinically trained in medical oncology/hematology, and scientifically trained in immunology. His ultimate goal is to better understand how the immune system can be directed to treat malignant disease and to translate basic science discoveries to the clinical setting. His expertise focuses on the development of novel immunotherapeutic approaches and the discovery of new antigens that can be effectively targeted for the treatment of cancer, specifically acute myeloid leukemia (AML).   Additionally, he has made critical discoveries regarding the expression, presentation and immunity generated by tumor-associated self-antigens in the setting of AML, multiple myeloma and breast cancer.  He is also involved in the development of T cell-based adoptive cellular therapies and T cell receptor-like antibodies.